Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Memphasys Limited, an Australian enterprise, is dedicated to the development, manufacturing, and distribution of advanced cell and protein separation technologies, alongside associated consumable goods, for the healthcare, veterinary, and biotechnology sectors. Its leading innovation is Felix, an automated device engineered to swiftly and gently isolate high-quality sperm from raw semen samples, primarily for use in human in vitro fertilization (IVF) procedures. The company's product portfolio also includes ROSA, a rapid oxidative stress assay; the Samson Device, designed for quick equine pregnancy prediction; SemPort, a system for central laboratory human semen analysis from geographically dispersed donors; and AI-Port, an ambient temperature semen transport solution for animal artificial insemination. Incorporated in 2006, the company was formerly known as NuSep Holdings Limited until its rebranding to Memphasys Limited in July 2016, and is headquartered in Homebush, Australia.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.